

Copper Signaling Axis as a Target for Prostate Cancer Th

Cancer Research

74, 5819-5831

DOI: [10.1158/0008-5472.can-13-3527](https://doi.org/10.1158/0008-5472.can-13-3527)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Copper unlocks therapeutic potential of disulfiram. <i>Nature Reviews Urology</i> , 2014, 11, 664-664.	1.9	6
2	Heterogeneous copper concentrations in cancerous human prostate tissues. <i>Prostate</i> , 2015, 75, 1510-1517.	1.2	22
3	Crystal Structure and Behavior in Solution of [Cu(HBPA) ₂]Cl ₂ ·4H ₂ O [HBPA = (2-hydroxybenzyl-2-pyridylmethyl)amine]. <i>Journal of Chemical Crystallography</i> , 2015, 45, 476-483.	0.5	6
4	Pharmacological activity of metal binding agents that alter copper bioavailability. <i>Dalton Transactions</i> , 2015, 44, 8760-8770.	1.6	76
5	Mechanistic basis of a combination d-penicillamine and platinum drugs synergistically inhibits tumor growth in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo. <i>Biochemical Pharmacology</i> , 2015, 95, 28-37.	2.0	28
6	Induction of apoptosis in leukemia cell lines by new copper(II) complexes containing naphthyl groups via interaction with death receptors. <i>Journal of Inorganic Biochemistry</i> , 2015, 153, 68-87.	1.5	25
7	Targeting copper in cancer therapy: "Copper That Cancer"™. <i>Metallomics</i> , 2015, 7, 1459-1476.	1.0	567
8	The cytotoxic mechanisms of disulfiram and copper(ii) in cancer cells. <i>Toxicology Research</i> , 2015, 4, 1439-1442.	0.9	66
9	Desferal regulates hCtr1 and transferrin receptor expression through Sp1 and exhibits synergistic cytotoxicity with platinum drugs in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo. <i>Oncotarget</i> , 2016, 7, 49310-49321.	0.8	19
10	Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution. <i>Oncotarget</i> , 2016, 7, 37064-37080.	0.8	69
11	Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 3860-3875.	3.2	142
12	Copper supplementation amplifies the anti-tumor effect of curcumin in oral cancer cells. <i>Phytomedicine</i> , 2016, 23, 1535-1544.	2.3	31
13	In vivo effect of copper status on cisplatin-induced nephrotoxicity. <i>BioMetals</i> , 2016, 29, 841-849.	1.8	7
14	In vitro and in vivo studies of the antineoplastic activity of copper (II) compounds against human leukemia THP-1 and murine melanoma B16-F10 cell lines. <i>European Journal of Medicinal Chemistry</i> , 2016, 123, 128-140.	2.6	38
15	The comparative effects of diethyldithiocarbamate-copper complex with established proteasome inhibitors on expression levels of CYP1A2/3A4 and their master regulators, aryl hydrocarbon and pregnane X receptor in primary cultures of human hepatocytes. <i>Fundamental and Clinical Pharmacology</i> , 2016, 30, 585-595.	1.0	4
16	Behind the Link between Copper and Angiogenesis: Established Mechanisms and an Overview on the Role of Vascular Copper Transport Systems. <i>Journal of Vascular Research</i> , 2015, 52, 172-196.	0.6	115
17	Dynamic internalization and recycling of a metal ion transporter: Cu homeostasis and hCTR1, the human Cu uptake system. <i>Journal of Cell Science</i> , 2016, 129, 1711-21.	1.2	50
18	Developing drugs targeting transition metal homeostasis. <i>Current Opinion in Chemical Biology</i> , 2017, 37, 26-32.	2.8	68

#	ARTICLE	IF	CITATIONS
19	An unlikely DNA cleaving agent: A photo-active trinuclear Cu(II) complex based on hexaazatriphenylene. <i>Journal of Inorganic Biochemistry</i> , 2017, 168, 55-66.	1.5	6
20	Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. <i>Nature</i> , 2017, 552, 194-199.	13.7	516
21	Recent views of heavy metals as possible risk factors and potential preventive and therapeutic agents in prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2017, 457, 57-72.	1.6	42
22	Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 641-657.	1.7	68
23	Cuprous oxide nanoparticles inhibit prostate cancer by attenuating the stemness of cancer cells via inhibition of the Wnt signaling pathway. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 2569-2579.	3.3	28
24	Cellular plasticity and the neuroendocrine phenotype in prostate cancer. <i>Nature Reviews Urology</i> , 2018, 15, 271-286.	1.9	273
25	The emerging role of copper-64 radiopharmaceuticals as cancer theranostics. <i>Drug Discovery Today</i> , 2018, 23, 1489-1501.	3.2	74
26	16. Copper Complexes in Cancer Therapy. , 2018, 18, 469-506.		36
27	Biokinetic and dosimetric aspects of $^{64}\text{CuCl}_2$ in human prostate cancer: possible theranostic implications. <i>EJNMMI Research</i> , 2018, 8, 18.	1.1	29
28	Copper signaling in the brain and beyond. <i>Journal of Biological Chemistry</i> , 2018, 293, 4628-4635.	1.6	121
29	Flavonoids-induced redox cycling of copper ions leads to generation of reactive oxygen species: A potential role in cancer chemoprevention. <i>International Journal of Biological Macromolecules</i> , 2018, 106, 569-578.	3.6	54
30	A New Type of Prostate Cancer Imaging: Will $^{64}\text{CuCl}_2$ PET/CT Flourish or Vanish?. <i>Journal of Nuclear Medicine</i> , 2018, 59, 442-443.	2.8	5
31	Balancing nanotoxicity and returns in health applications: The Prisoner's Dilemma. <i>Toxicology</i> , 2018, 393, 83-89.	2.0	7
32	Iron and Copper Intracellular Chelation as an Anticancer Drug Strategy. <i>Inorganics</i> , 2018, 6, 126.	1.2	64
33	Anti-cancer effects of disulfiram in head and neck squamous cell carcinoma via autophagic cell death. <i>PLoS ONE</i> , 2018, 13, e0203069.	1.1	31
34	Drug Repositioning for Effective Prostate Cancer Treatment. <i>Frontiers in Physiology</i> , 2018, 9, 500.	1.3	85
35	Investigation of the key chemical structures involved in the anticancer activity of disulfiram in A549 non-small cell lung cancer cell line. <i>BMC Cancer</i> , 2018, 18, 753.	1.1	31
36	Leveraging γ -Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. <i>Angewandte Chemie</i> , 2018, 130, 12962-12966.	1.6	8

#	ARTICLE	IF	CITATIONS
37	Molecular underpinnings of enzalutamide resistance. <i>Endocrine-Related Cancer</i> , 2018, 25, R545-R557.	1.6	28
38	Leveraging γ -Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 12780-12784.	7.2	53
39	Metal/Metal Oxide Nanoparticles for Cancer Therapy. <i>Nanomedicine and Nanotoxicology</i> , 2018, , 341-364.	0.1	11
40	Copper homeostasis as target of both consolidated and innovative strategies of anti-tumor therapy. <i>Journal of Trace Elements in Medicine and Biology</i> , 2019, 55, 204-213.	1.5	56
41	Enhanced Tumor-Specific Disulfiram Chemotherapy by <i>In Situ</i> Cu^{2+} Chelation-Initiated Nontoxicity-to-Toxicity Transition. <i>Journal of the American Chemical Society</i> , 2019, 141, 11531-11539.	6.6	237
42	ALDH-Dependent Glycolytic Activation Mediates Stemness and Paclitaxel Resistance in Patient-Derived Spheroid Models of Uterine Endometrial Cancer. <i>Stem Cell Reports</i> , 2019, 13, 730-746.	2.3	59
43	Systematic chemical screening identifies disulfiram as a repurposed drug that enhances sensitivity to cisplatin in bladder cancer: a summary of preclinical studies. <i>British Journal of Cancer</i> , 2019, 121, 1027-1038.	2.9	36
44	Neuroendocrine Differentiation of Prostate Cancer—An Intriguing Example of Tumor Evolution at Play. <i>Cancers</i> , 2019, 11, 1405.	1.7	70
45	Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status. <i>Ecancermedicalscience</i> , 2019, 13, 890.	0.6	12
46	Blockage of SLC31A1-dependent copper absorption increases pancreatic cancer cell autophagy to resist cell death. <i>Cell Proliferation</i> , 2019, 52, e12568.	2.4	90
47	Inhibition of $\text{ERR}\alpha$ Prevents Mitochondrial Pyruvate Uptake Exposing NADPH-Generating Pathways as Targetable Vulnerabilities in Breast Cancer. <i>Cell Reports</i> , 2019, 27, 3587-3601.e4.	2.9	29
48	Dual-time-point ^{64}Cu -PSMA PET/CT in patients suffering from prostate cancer. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2019, 62, 523-532.	0.5	22
49	Enhancing the Effect of Pharmacological Ascorbate in Cancer Therapy via Acid-Triggered Ferritin Nanoparticles. <i>Advanced Biology</i> , 2019, 3, 1900006.	3.0	3
50	Copper as the Target for Anticancer Nanomedicine. <i>Advanced Therapeutics</i> , 2019, 2, 1800147.	1.6	29
51	12. Copper Depletion as a Therapeutic Strategy in Cancer. , 2019, 19, 303-330.		33
52	Development of Injectable PEGylated Liposome Encapsulating Disulfiram for Colorectal Cancer Treatment. <i>Pharmaceutics</i> , 2019, 11, 610.	2.0	53
53	Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram. <i>Prostate</i> , 2019, 79, 352-362.	1.2	23
54	Arsenic trioxide encapsulated liposomes prepared via copper acetate gradient loading method and its antitumor efficiency. <i>Asian Journal of Pharmaceutical Sciences</i> , 2020, 15, 365-373.	4.3	13

#	ARTICLE	IF	CITATIONS
55	A disulfiram-loaded electrospun poly(vinylidene fluoride) nanofibrous scaffold for cancer treatment. <i>Nanotechnology</i> , 2020, 31, 115101.	1.3	11
56	InÂvitro and inÂvivo antitumoral activity of a ternary copper (II) complex. <i>Biochemical and Biophysical Research Communications</i> , 2020, 533, 1021-1026.	1.0	7
57	The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy. <i>Cancers</i> , 2020, 12, 3594.	1.7	126
58	Biomedical applications of copper ionophores. <i>Coordination Chemistry Reviews</i> , 2020, 422, 213474.	9.5	69
59	Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II. <i>Cancers</i> , 2020, 12, 2863.	1.7	97
60	Graphene Oxide Nanosheets Tailored With Aromatic Dipeptide Nanoassemblies for a Tuneable Interaction With Cell Membranes. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 427.	2.0	6
61	Cystathionine-Î²-synthase: Molecular Regulation and Pharmacological Inhibition. <i>Biomolecules</i> , 2020, 10, 697.	1.8	113
62	Epigenetic modulations and lineage plasticity in advanced prostate cancer. <i>Annals of Oncology</i> , 2020, 31, 470-479.	0.6	103
63	Isoquinoline thiosemicarbazone displays potent anticancer activity with in vivo efficacy against aggressive leukemias. <i>RSC Medicinal Chemistry</i> , 2020, 11, 392-410.	1.7	6
64	The Personalisation of Glioblastoma Treatment Using Whole Exome Sequencing: A Pilot Study. <i>Genes</i> , 2020, 11, 173.	1.0	3
65	Dithiocarbamate prodrugs activated by prostate specific antigen to target prostate cancer. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127148.	1.0	12
66	Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment. <i>Seminars in Cancer Biology</i> , 2021, 68, 105-122.	4.3	27
67	Disulfiram: a novel repurposed drug for cancer therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 159-172.	1.1	68
68	Therapeutic potential of endogenous hydrogen sulfide inhibition in breast cancer (Review). <i>Oncology Reports</i> , 2021, 45, .	1.2	14
69	Age-Related Changes in Zinc, Copper and Selenium Levels in the Human Prostate. <i>Nutrients</i> , 2021, 13, 1403.	1.7	4
70	Therapeutic potential of a copper complex loaded in pH-sensitive long circulating liposomes for colon cancer management. <i>International Journal of Pharmaceutics</i> , 2021, 599, 120463.	2.6	27
71	Association between renin-angiotensin system and chronic lung allograft dysfunction. <i>European Respiratory Journal</i> , 2021, 58, 2002975.	3.1	6
72	Disulfiram and 6-Thioguanine synergistically inhibit the enzymatic activities of USP2 and USP21. <i>International Journal of Biological Macromolecules</i> , 2021, 176, 490-497.	3.6	11

#	ARTICLE	IF	CITATIONS
73	Modulation of Intracellular Copper Levels as the Mechanism of Action of Anticancer Copper Complexes: Clinical Relevance. <i>Biomedicines</i> , 2021, 9, 852.	1.4	93
74	Understanding the Therapeutic Potential of Ascorbic Acid in the Battle to Overcome Cancer. <i>Biomolecules</i> , 2021, 11, 1130.	1.8	22
75	Development of lactobionic acid conjugated-copper chelators as anticancer candidates for hepatocellular carcinoma. <i>Arabian Journal of Chemistry</i> , 2021, 14, 103241.	2.3	5
77	Tetraethylthiuram disulphide alleviates pulmonary fibrosis through modulating transforming growth factor- β signalling. <i>Pharmacological Research</i> , 2021, 174, 105923.	3.1	3
78	Hypoxia imaging and theranostic potential of $[^{64}\text{Cu}][\text{Cu}(\text{ATSM})]$ and ionic Cu(II) salts: a review of current evidence and discussion of the retention mechanisms. <i>EJNMMI Research</i> , 2020, 10, 33.	1.1	34
79	Disulfiram anti-cancer efficacy without copper overload is enhanced by extracellular H ₂ O ₂ generation: antagonism by tetrathiomolybdate. <i>Oncotarget</i> , 2015, 6, 29771-29781.	0.8	30
80	Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 2796-2808.	0.8	57
81	Cancer Pro-oxidant Therapy Through Copper Redox Cycling: Repurposing Disulfiram and Tetrathiomolybdate. <i>Current Pharmaceutical Design</i> , 2020, 26, 4461-4466.	0.9	15
82	Molecular imaging and therapy targeting copper metabolism in hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2016, 22, 221.	1.4	42
83	Copper in tumors and the use of copper-based compounds in cancer treatment. <i>Journal of Inorganic Biochemistry</i> , 2022, 226, 111634.	1.5	109
84	Repurposing Disulfiram for Targeting of Glioblastoma Stem Cells: An In Vitro Study. <i>Biomolecules</i> , 2021, 11, 1561.	1.8	8
85	Repositioning an Old Anti-Alcoholism Drug: Disulfiram as a Selective, Effective and Economical Anticancer Agent. <i>Journal of Developing Drugs</i> , 2016, 05, .	0.9	1
86	Reactive Oxygen Species in Melanoma Etiology. , 2016, , 259-275.		0
87	Leveraging disulfiram to treat cancer: Mechanisms of action, delivery strategies, and treatment regimens. <i>Biomaterials</i> , 2022, 281, 121335.	5.7	57
88	Copper (I±)-cis-platinum-loaded nanogels as an adjuvant potentiate disulfiram's antitumor efficacy. <i>Biomaterials Science</i> , 2022, 10, 1384-1392.	2.6	2
89	Applications of radiocomplexes with thiosemicarbazones and bis(thiosemicarbazones) in diagnostic and therapeutic nuclear medicine. <i>Coordination Chemistry Reviews</i> , 2022, 458, 214418.	9.5	26
90	Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing. <i>Medical Sciences (Basel, Switzerland)</i> , 2022, 10, 15.	1.3	13
91	Recent Advances in Cancer Imaging with $^{64}\text{CuCl}_2$ PET/CT. <i>Nuclear Medicine and Molecular Imaging</i> , 2022, 56, 80-85.	0.6	4

#	ARTICLE	IF	CITATIONS
92	Population-level Patterns of Prostate Cancer Occurrence: Disparities in Virginia. <i>Current Molecular Biology Reports</i> , 2022, 8, 1-8.	0.8	0
93	Anti-Cancer Effects of Disulfiram in Cervical Cancer Cell Lines Are Mediated by Both Autophagy and Apoptosis. <i>Bulletin of Experimental Biology and Medicine</i> , 2022, 172, 642-648.	0.3	1
94	Selective Targeting of Cancer Cells by Copper Ionophores: An Overview. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 841814.	1.6	182
95	Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2022, 82, 858-866.	1.2	10
96	Essential Elements and Isoflavonoids in the Prevention of Prostate Cancer. <i>Nutrients</i> , 2022, 14, 1225.	1.7	6
97	Anticancer effects of disulfiram in T-cell malignancies through NPL4-mediated ubiquitin-proteasome pathway. <i>Journal of Leukocyte Biology</i> , 2022, 112, 919-929.	1.5	16
98	Copper enhances genotoxic drug resistance via ATOX1 activated DNA damage repair. <i>Cancer Letters</i> , 2022, 536, 215651.	3.2	18
99	Copper depletion modulates mitochondrial oxidative phosphorylation to impair triple negative breast cancer metastasis. <i>Nature Communications</i> , 2021, 12, 7311.	5.8	101
101	Cytotoxic effect of disulfiram/copper on human cervical cancer cell lines and LGR5-positive cancer stem-like cells. <i>BMC Cancer</i> , 2022, 22, 521.	1.1	5
102	Emerging Roles of the Copper-CTR1 Axis in Tumorigenesis. <i>Molecular Cancer Research</i> , 2022, 20, 1339-1353.	1.5	8
103	Cuproptosis-Related Gene SLC31A1, FDX1 and ATP7B Polymorphisms are Associated with Risk of Lung Cancer. <i>Pharmacogenomics and Personalized Medicine</i> , 0, Volume 15, 733-742.	0.4	19
104	Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	44
105	The combined prognostic model of copper-dependent to predict the prognosis of pancreatic cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	4
106	Cuproptosis-related gene index: A predictor for pancreatic cancer prognosis, immunotherapy efficacy, and chemosensitivity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
107	Cu@graphene as antibody-free fluorosensor for prostate-specific antigen (PSA). <i>Materials Today Chemistry</i> , 2022, 26, 101196.	1.7	0
108	Molecular Subtypes Based on Cuproptosis-Related Genes and Tumor Microenvironment Infiltration Characterization in Colorectal Cancer. <i>Journal of Oncology</i> , 2022, 2022, 1-19.	0.6	2
109	Relationship between copper and immunity: The potential role of copper in tumor immunity. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	22
110	Development of a copper metabolism-related gene signature in lung adenocarcinoma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10

#	ARTICLE	IF	CITATIONS
111	Effect of Copper Chelators via the TGF- β ² Signaling Pathway on Glioblastoma Cell Invasion. <i>Molecules</i> , 2022, 27, 8851.	1.7	3
112	The cuproptosis related genes signature predicts the prognosis and correlates with the immune status of clear cell renal cell carcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
113	Cuproptosis-related LncRNAs signature as biomarker of prognosis and immune infiltration in pancreatic cancer. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	1
114	Targeting Copper in Cancer Imaging and Therapy: A New Theragnostic Agent. <i>Journal of Clinical Medicine</i> , 2023, 12, 223.	1.0	11
115	DDTC-Cu(I) based metal-organic framework (MOF) for targeted melanoma therapy by inducing SLC7A11/GPX4-mediated ferroptosis. <i>Colloids and Surfaces B: Biointerfaces</i> , 2023, 225, 113253.	2.5	12
116	Comprehensive analysis of cuproptosis-related prognostic gene signature and tumor immune microenvironment in HCC. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	3
118	Identification of copper metabolism-related subtypes and establishment of the prognostic model in ovarian cancer. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	39
119	Copper overload impairs hematopoietic stem and progenitor cell proliferation via prompting HSF1/SP1 aggregation and the subsequently downregulating FOXM1-Cytoskeleton axis. <i>IScience</i> , 2023, 26, 106406.	1.9	6
122	Plant-derived chelators and ionophores as potential therapeutics for metabolic diseases. <i>Chemical Society Reviews</i> , 0, , .	18.7	0
126	The immunomodulatory function and antitumor effect of disulfiram: paving the way for novel cancer therapeutics. <i>Discover Oncology</i> , 2023, 14, .	0.8	2